Arrowhead Pharmaceuticals (ARWR) Times Interest Earned (2011 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Times Interest Earned came in at -$0.85 in Q1 2026, down 104.84% YoY from $17.62 in Q1 2025, and down 454.39% on a QoQ basis from $0.24 in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Times Interest Earned (2011 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 16 years of Times Interest Earned data on file, last reported at -$0.85 in Q1 2026.
- Quarterly Times Interest Earned fell 104.84% year-over-year to -$0.85 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.34 (up 54.82% YoY) and the FY2025 annual result came in at $1.1, up 182.19% from the prior year.
- Times Interest Earned retreated to -$0.85 in Q1 2026, from $0.24 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $19.34 in Q3 2024 to a low of -$42.89 in Q2 2022.
- A 5-year average of -$4.38 and a median of -$0.85 in 2025 frame the typical range for Times Interest Earned.
- The widest YoY moves for Times Interest Earned: up 11984.06% in 2022, down 30135.34% in 2022.
- Tracing ARWR's Times Interest Earned over 5 years: stood at -$14.79 in 2022, then sank by 72.03% to -$25.44 in 2023, then surged by 70.69% to -$7.46 in 2024, then surged by 103.23% to $0.24 in 2025, then sank by 454.39% to -$0.85 in 2026.
- The last three Times Interest Earned figures came in at -$0.85 (Q1 2026), $0.24 (Q4 2025), and -$0.85 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | -0.84 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.84 |
| Mar 31, 2026 | -0.85 |
| Dec 31, 2025 | 0.24 |
| Sep 30, 2025 | -0.85 |
| Jun 30, 2025 | -0.94 |
| Mar 31, 2025 | 17.62 |
| Dec 31, 2024 | -7.46 |
| Sep 30, 2024 | 19.34 |
| Jun 30, 2024 | -34.58 |
| Mar 31, 2024 | -17.42 |
| Dec 31, 2023 | -25.44 |
| Sep 30, 2023 | 9.97 |
| Jun 30, 2023 | -0.70 |
| Mar 31, 2023 | 9.52 |
| Dec 31, 2022 | -14.79 |
| Jun 30, 2022 | -42.89 |
| Mar 31, 2022 | 19.14 |
| Dec 31, 2021 | -0.42 |
| Sep 30, 2021 | -72.09 |
| Jun 30, 2021 | -0.14 |